Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-05-13T15:35:43.868Z Has data issue: false hasContentIssue false
  • English
  • Français

Hepatitis B Immunization Update

Published online by Cambridge University Press:  21 June 2016

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Infection Control & Hospital Epidemiology , Volume 10 , Issue 12 , December 1989 , pp. 541 - 546
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1989

References

1.Robinson, W. Hepatitis B virus and hepatitis delta virus. In: Mandell, GL, Douglas, RG, Bennett, JE, Eds. Principles and practice of infectious diseases. 3rd ed. New York, NY: Churchill Livingstone Inc; 1990:1204–1231.Google Scholar
2.Centers for Disease Control. ACIP: recommendations for protection against viral hepatitis. MMWR. 1985;34:313–335.Google Scholar
3.Centers for Disease Control. Guidelines for prevention of transmission of human immuondeficiency virus and hepatitis B virus to health care and public-safety workers. MMWR. 1989;38:3–35.Google Scholar
3.Jagger, J, Hunt, EH, Brand-Elnaggar, J, Pearson, RD. Rates of needlestick injury caused by various devices in a university hospital. N Engl J Med. 1988;319:284–288.Google Scholar
5.Seeff, LB, Wright, EC, Zimmerman, HJ, et al.Type B hepatitis after needlestick exposure: prevention with hepatitis B immune globulin. Ann Intern Med. 1978;88:285–293.Google Scholar
6.Werner, BG, Grady, GE, Accidental hepatitis-B-surface-antigen-positive inoculations: use of e antigen to estimate infectivity. Ann Intern Med. 1982;97:367–369.Google Scholar
7.Davis, LG, Weber, DJ, Lemon, SM. Horizontal transmission of hepatitis B virus. Lanced. 1989;1:889–894.Google Scholar
8.Bancroft, WH, Snitbhan, R, Scott, RM, et al.Transmission of hepatitis B virus to gibbons by exposure to human saliva containing hepatitis B surface antigen. Infect Dis. 1977;135:79–85.Google Scholar
9.Osterholm, MT, Bravo, ER, Cmsson, JT. Polisky, HF, Hanson, M. Lack of transmission of viral hepatitis type B after oral exposure to HBsAg-positive saliva. Br Med J. 1979;2:1263–1264.Google Scholar
10.Glaser, JB, Nadler, JP. Hepatitis B virus in a cardiopulmonary resuscitation training course: risk of transmission from a surface antigen-positive participant. Arch Intern. Med. 1985;145:1653–1655.Google Scholar
11.Osterholm, MT, Max, BJ, Hanson, M, et al.Potential risk of salivary-mediated viral hepatitis type B transmission from oral exposure to fomites. J Hyg Camb. 1979;83:487–490.Google Scholar
12.Cancio-Bello, TP, de Medina, M, Shorey, J, Valledor, MD, Schiff, ER. An institutional outbreak of hepatitis B related to a human biting carrier. J Infect Dis. 1982;146:652–656.Google Scholar
13.Bond, WW, Favero, MS, Petersen, NJ, Gravelle, CR, Eben, JW, Maynard, JE. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1981;1:550–551.Google Scholar
14.Centers for Disease Control. Hepatitis B associated with jet gun infection-California. MMWR. 1986;35:373–376.Google Scholar
15.Morris, IM, Cattle, DS, Smits, BJ. Endoscopy and transmission of hepatitis B. Lancet. 1975;2:1152.Google Scholar
16.Oren, I, Hershow, RC, Ben-Porath, E, et al.A common-source outbreak of fulminant hepatitis B in a hospital. Ann Intern Med. 1989;110:691–698.Google Scholar
17.Lauer, JL, VanDrunen, NA, Washburn, JW, Balfour, HH Jr.Transmission of Hepatitis B virus in clinical laboratory areas. J Infect Dis. 1979;140:513–516.Google Scholar
18.Pattison, CP, Boyer, KM, Maynard, JE, Kelly, PC. Epidemic hepatitis in a clinical laboratory: possible association with computer card handling. JAMA. 1974;230:854–857.Google Scholar
19.Alter, HJ, Chalmers, TC, Freeman, BM, et al.Health-care workers positive for hepatitis B surface antigen: are their contacts at risk? N Engl J Med. 1975;292:454–457.Google Scholar
20.Grob, PJ, Bischof, B, Naeff, F. Cluster of hepatitis B transmitted by a physician. Lancet. 1981;2:1218–1220.Google Scholar
21.Grob, PJ, Moeschlin, P. Risk to contacts of a medical practitioner carrying HBsAg. New Engl J Med 1975;293:197.Google Scholar
22.Levin, ML, Maddrey, WC, Wands, JR, Mendeloff, Al. Hepatitis B transmission by dentists. JAMA. 1974;1228:1139–1140.Google Scholar
23.Hadler, SC, Sorley, DL, Aeree, KH, et al.An outbreak of hepatitis B in a dental practice. Ann Intern Med. 1981;95:133–138.Google Scholar
24.Rimland, D, Parkin, WE, Miller, GB, Schrack, WD. Hepatitis B outbreak traced to an oral surgeon. N Engl J Med 1977;296:953–958.Google Scholar
25.Centers for Disease Control. Outbreak of hepatitis B associated with an oral surgeon-New Hampshire. MMWR. 1987;36:132–133.Google Scholar
26.Lettau, LA, Smith, JD, Williams, D, et al.Transmission of hepatitis B with resultant restriction of surgical practice. JAMA. 1986;255:934–937.Google Scholar
27.Garibaldi, RA, Rasmussen, CM, Holmes, AW, Gregg, MD. Hospital-acquired serum hepatitis: report of an outbreak. JAMA. 1972;219:1577–1580.Google Scholar
28.Hilleman, MR. Yeast recombinant hepatitis B vaccine. Infection. 1987;15:3–7.Google Scholar
29.Francis, DP, Hadler, SC, Thompson, SE, et al.The prevention of hepatitis B with vaccine: report of the centers for disease control multi-center efficacy trial among homosexual men. Ann Intern Med. 1982;97:362–366.Google Scholar
30.Szmuness, W, Stevens, CE. Zang, EA, Harley, EJ, Kellner, A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981;1:377–385.Google Scholar
31.Szmuness, W, Stevens, CE, Harley, EJ, et al.Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population m the United States. N Engl J Med 1980;303:833–841.Google Scholar
32.Dienstag, JL, Werner, BG, Polk, BF, et al.Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med. 1984;101:34–40.Google Scholar
33.Szmuness, W, Stevens, CE, Harley, EJ, et al.Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med. 1982;307:1481–1486.Google Scholar
34.Horowitz, MM, Ershler, WB, McKinney, WP, Battiola, RJ. Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. Ann Intern Med. 1988;108:185–189.Google Scholar
35.Craven, DE, Awdeh, ZL, Kunches, LM, et al.Nonresponsiveness to hepatitis B vaccine in health care workers. Ann Intern Med. 1986;105:356–360.Google Scholar
36.de Lalla, F, Rinaldi, E, Santoro, D, et al.Immune response to hepatitis B vaccine given at different injection sites and by different routes: a controlled randomized study. Eur J Epidemiol. 1988;4:256–258.Google Scholar
37.Hollinger, FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med. 1989;87:3A–36S-3A-40S.Google Scholar
38.Laplanche, A, Courouce, AM, Benhamou, E, Jungers, P, Crosmer, J. Responses to hepatitis B vaccine. Lancet. 1982;1:222.Google Scholar
39.Pasko, MT, Bartholomew, WR, Beam, TR, Amsterdam, D, Cunningham, EE. Long-term evaluation of the hepatitis B vaccine (Heptavax-B) in hemodialysis patients. Am J Kidney Dis. 1988;11:326–331.Google Scholar
40.Seaworth, B, Drucker, J, Starling, J, Drucker, R, Stevens, C, Hamilton, J. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis. 1988;157:332–337.Google Scholar
41.Collier, AC, Corey, L, Murphy, VL, Handsheld, HH. Antibody to human itnmunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med. 1988;109:101–105.Google Scholar
42.Mannucci, PM, Zanetti, AR, Gringeri, A, et al.Long-term immuno-genicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs. Arch Intern Med. 1989; 149:1333–1337.Google Scholar
43.Zanetti, AR, Mannucci, PM, Tanzi, E, et al.Hepatitis B vaccination of 113 hemophiliacs: lower antibody response in anti-LAVIHTLV-III-positive patients. Am J Hematol. 1986;23:339–345.Google Scholar
44.Stevens, CE, Taylor, PE, Tong, MJ, et al.Yeast-recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA. 1987;257:2612–2616.Google Scholar
45.Szmuness, W, Oleszko, WR, Stevens, CE, Goodman, A. Passive-active immunization against hepatitis B: immunogenicity studies in adult Americans. Lancet. 1981;1:575–577.Google Scholar
46.Gerety, RJ, Ellis, RW, Zajac, BA, West, DJ. Two superb vaccines against hepatitis B in Mexican standoff. JAMA. 1988;259:2402–2404.Google Scholar
47.Hadler, SC, Francis, DP, Maynard, JE, et al.Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986;315:209–214.Google Scholar
48.Krugman, S, Davidson, M. Hepatitis B vaccine: prospects for duration of immunity. Yale J Biol Med 1987;60:333–338.Google Scholar
49.Andre, FE, Safary, A. Clinical Experience with a yeast-derived hepatitis B vaccine. In: Viral Hepatitis and Liver Disease. New York, NY: Alan R. Liss, Inc;1988;1025–1030.Google Scholar
50.Bergamini, F, Zanetti, A. Immunogenicity of yeast-derived hepatitis B vaccines in young adults. Postgrad Med J. 1987;63(suppl 2): 137–138.Google Scholar
51.Davidson, M, Krugman, S. Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: immunogenicity and effect of a booster dose. J Infect 1986; 13(suppl A):31–38.Google Scholar
52.Crovari, P, Crovari, PC, Petrilli, RC, leardi, GC, Bonanni, P, Immunogenicity of a yeast-derived hepatitis B vaccine (Engerix-B) in healthy young adults. Postgrad Med J. 1987;63(suppl 2):161–164.Google Scholar
53.Dandolos, E, Roumeliotou-Karayannis, A, Richardson, SC, Papaevan-gelov, G. Safety and immunogenicity of a recombinant hepatitis B vaccine. J Med Virol. 1985;17:57–62.Google Scholar
54.Hollinger, FB, Troisi, CL, Pepe, PE. Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast. J Infect Dis. 1986;153:156–159.Google Scholar
55.Just, M, Berger, R, Just, V. Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma-derived vaccine in young adults. Postgrad Med J. 1987;63(suppl 2):l2l–l23.Google Scholar
56.Scheiermann, N, Gesemann, KM, Kreuzfelder, E, Paar, D. Effects of a recombinant yeast-derived hepatitis B vaccine in healthy adults. Postgrad Med J. 1987;63(suppl 2):115–119.Google Scholar
57.Andre, FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med. 1989;3A–14S-3A-20S.Google Scholar
58.Bruguera, A, Cremades, M, Mayor, A, Sanchez Tapies, JM, Rodes, J. Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients. Postgrad Med J. 1987;63(suppl 2):155–158.Google Scholar
59.Jilg, W, Schmidt, M, Deinhardt, F. Four-year experience with a recombinant hepatitis B vaccine. Infection. 1989;17:70–76.Google Scholar
60.Shaw, FE Jr., Graham, DJ, Guess, HA, et al.Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination: experience of the first three years. Am J Epidemiol. 1988;127:337–352.Google Scholar
61.Brightman, CAJ, Scadding, GK, Dumbreck, LA, Latchman, Y, Brostoff, J. Yeast-derived hepatitis B vaccine and yeast sensitivity. Lancet. 1989;2:903.Google Scholar
62.Wiedermann, G, Scheiner, O, Ambrosch, F, et al.Lack of induction of IgE and IgG antibodies to yeast in humans immunized with recombinant hepatitis B vaccines. Int Arch Allergy Appi Immunol. 1988;85:130–132.Google Scholar
63.Hackenberger, F. Thiomersal. In: Dukes, MNG, ed. Meyler's Side Effects of Drugs: An Encyclopedia of Adverse Reactions and Interaction. Elsevier NY;1984:430.Google Scholar
64.Wismans, P, van Hattum, J, Stelling, T, Poel, J, de Gast, GC. Effect of supplementary vaccination in healthy non-responders to hepatitis B vaccination. Hepatogastroenterology. 1988;35:78–79.Google Scholar
65.Ambrosch, F, Frisch-Niggemeyer, W, Kremsner, P, et al.Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subject. Postgrad Med J. 1987;63(suppl 2):129–135.Google Scholar
66.Jilg, W, Schmidt, M, Deinhardt, F, Zachoval, R. Hepatitis B vaccination: how long does protection last? Lancet. 1984;2:458.Google Scholar
67.Laplanche, A, Courouce, AM, Benhamou, E, Jungers, P. Timing of hepatitis B revaccination in healthy adults. Lancet. 1987;1:1206–1207.Google Scholar
68.Nommensen, FE, Go, ST, McLaren, DM. Half-life of HBs antibody after hepatitis B vaccination: an aid to timing of booster vaccination. Lancet. 1989;2:847–849.Google Scholar
69.Jilg, W, Schmidt, M, Deinhardt, F. Immune response to hepatitis B revaccination. J Med Virol. 1988;24:377–384.Google Scholar
70.Matsaniotis, N, Kattamis, C, Laskari, S, Tzeti, M, Markosoglou, D. When should at-risk patients with thalassaemia be boosted with hepatitis B vaccine? Lancet. 1987;1:1321.Google Scholar
71.Wismans, PJ, van Hattum, J, Mudde, GC, Endeman, HJ, Poel, J, de Gast, CC. Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. J Hepatol. 1989;8:236–240.Google Scholar
72.Wilhams, WW, Preblub, SR, Reichelderfer, PS, Hadler, SC. Vaccines of importance in the hospital setting. Infect Disease Clin North Am. 1989;3:701–722.Google Scholar
73.Snyder, MB. Management of health care workers remotely vaccinated for hepatitis B who sustain significant blood and body fluid exposures. Infect Control Hosp Epidemiol. 1988;9:462–464.Google Scholar
74.Wahl, M, Hermodsson, S, Iwarson, S. Hepatitis B vaccination with short dose intervals-a possible alternative for post-exposure prophylaxis? Infect 1988;16:229–232.Google Scholar
75.Jilg, W, Schmidt, M, Deinhardt, F. Prolonged immunity after late booster doses of hepatitis B vaccine. J Infect Dis. 1988;157:1267–1269.Google Scholar
76.Irving, WL, Adler, M, Kurtz, JB, Juel-Jensen, B. Intradermal vaccination against hepatitis B. Lancet. 1986;2:1340.Google Scholar
77.Pathak, UN, Diuawari, JB, Chawla, Y, Sokhey, CS, Sharma, BK, Ganguly, NK. Immunogenicity and side effects of low dose intradermally administered hepatitis B vaccine. Indian J Gastroenterol. 1988;7:113–114.Google Scholar
78.Rajadhyaksh, KP, Haridas, V, Plumber, ST, et al.Efficacy of low-dose intradermal hepatitis B vaccine. Indian J Gastroenterol 1988;7:111–112.Google Scholar
79.Miller, KD, Gibbs, RD, Mulligan, MM, et al.Intradermal hepatitis B virus vaccine: immunogenicity and side-effects in adults. Lancet. 1983;2:1454–1456.Google Scholar
80.Redfield, RR, Innis, BL, Scott, RM, et al.Clinical evaluation of low-dose administered hepatitis b virus vaccine: a cost reduction strategy. JAMA. 1985;254:3203–3206.Google Scholar
81.Clarke, JA, Hollinger, FB, Lewis, E, Russell, LA, Miller, CH, Huntley, A, et al.Intradermal inoculation with Heptavax-B: immune response and histologic evaluation of injection sites. JAMA. 1989;262:2567–2571.Google Scholar
82.Zuckerman, AJ. Appraisal of intradermal immunization against hepatitis B. Lancet. 1987;1:435–436.Google Scholar
83.Zoulek, GTLorbeer, B, Jilg, W, Deinhardt, F. Evaluation of a reduced dose of hepatitis B vaccine administered intradermally. J Med Virol. 1984;14:27–32.Google Scholar
84.Zoulek, G, Lorbeer, B, Jilg, W, Deinhardt, F. Persistence of anti-HBs after intradermal inoculation of reduced doses of hepatitis B vaccine. Lancet. 1984;2:983–984.Google Scholar
85.Halsey, NA, Reppert, EJ, Margohs, HS, Francis, DP, fields, HA. Intradermal hepatitis B vaccination in an abbreviated schedule. Vaccine. 1986;4:228–232.Google Scholar
86.Sielko, DG, Anda, RF, McGee, HB, et al.Hepatitis B vaccination programs for hospital workers: results of a statewide survey. Am J Infect Control 1988;16:193–197.Google Scholar
87.Scapa, E, Karpuch, J, Waron, M, Eshchar, J. Attitude of hospital personnel toward hepatitis B vaccination. Am J Gastroenterol. 1989;84:400–402.Google Scholar
88.Anderson, AC, Hodges, GR. Acceptance of hepatitis B vaccine among high-risk health care workers. Am J Infect Control. 1983;11:207–211.Google Scholar
89.Centers for Disease Control. ACIP: update on hepatitis B prevention. MMWR. 1987;36:353–366.Google Scholar
90.Hanacik, LJ, Franson, TR, Gollup, JD, Rytel, MW. Implementing a successful hepatitis B vaccination program. Infect Control. 1985;6:306–309.Google Scholar
91.Levy, BS, Harris, JC, Smith, JL, et al.Hepatitis B in ward and clinical laboratory employees of a general hospital. Am J Epidemiol. 1977;106:330–335.Google Scholar
92.Dienstag, JL, Ryan, DM. Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? Am J Epidemiol. 1982;115:26–39.Google Scholar
93.Harris, IR, Finger, RF. Kobavashi, TM. et al.The low risk of heoatitis B in rural hospitals: results of ‘a se&epidemiologic survey. JAMA. 1984;252:3270–3272.Google Scholar
94.Occupational Safety and Health Administration. Occupational exposure to bloodborne pathogens; proposed rule and notice of hearing. Federal Register. 54:23042–23139.Google Scholar
95.Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, heoatitis B virus, and other bloodborne pathogens in health care settings. MMWR. 1988;37:377–388.Google Scholar